Cite
Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
MLA
Molina, David, et al. “Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.” PLoS ONE, vol. 11, no. 8, Aug. 2016, pp. 1–16. EBSCOhost, https://doi.org/10.1371/journal.pone.0161484.
APA
Molina, D., Pérez-Beteta, J., Martínez-González, A., Sepúlveda, J. M., Peralta, S., Gil-Gil, M. J., Reynes, G., Herrero, A., De Las Peñas, R., Luque, R., Capellades, J., Balaña, C., & Pérez-García, V. M. (2016). Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients. PLoS ONE, 11(8), 1–16. https://doi.org/10.1371/journal.pone.0161484
Chicago
Molina, David, Julián Pérez-Beteta, Alicia Martínez-González, Juan M. Sepúlveda, Sergi Peralta, Miguel J. Gil-Gil, Gaspar Reynes, et al. 2016. “Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.” PLoS ONE 11 (8): 1–16. doi:10.1371/journal.pone.0161484.